Publication | Open Access

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer

SclerostinBone Morphogenic ProteinFms-dependent Osteoclast DifferentiationOsteoporosisRadiation OncologyMedicineCell BiologyOrthopaedic SurgeryTumor MicroenvironmentTyrosine Kinase Inhibitor